Therapeutic effects of Curcumin capsule in patients with amyotrophic lateral sclerosis
Not Applicable
Completed
- Conditions
- Amyotrophic lateral sclerosis(AlS).Motor neuron disease
- Registration Number
- IRCT2015062411424N3
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients with an age range of 18 to 85; Probable or definite ALS (based on revised El Escorial criteria); Time passed since onset of the symptoms till inclusion be 2 years or less; Mild to moderate disability (based on ALSFRS-r)
Exclusion criteria:
Familial ALS in first-degree relatives; Pregnancy or breastfeeding; Severe renal, liver or heart dysfunction; HIV positive patients; Prominant cognitive impairment
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patients clinical function changes. Timepoint: baseline,3 months after intervention. Method of measurement: ALS Functional Rating Scale.
- Secondary Outcome Measures
Name Time Method Compound muscle action potential (CMAP) changes in ulnar nerve. Timepoint: baseline, 3 months after intervention. Method of measurement: EMG-NCV.;Muscle strength changes. Timepoint: baseline, 3 months after intervention. Method of measurement: Manual muscle testing.;Compound muscle action potential (CMAP) changes in proneal nerve. Timepoint: baseline, 3 months after intervention. Method of measurement: EMG-NCV.;Quality of life. Timepoint: baseline, 3 months after intervention. Method of measurement: ALSAQ-40.;Medication side effects. Timepoint: 3 months after intervention. Method of measurement: questionnaire.